Rimtuzalcap (C007B-415999)

Rimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels). Rimtuzalcap can be used for the research of movement disorders including essential tremor (ET) and spinocerebellar ataxia (SCA).In VitroRimtuzalcap (Compound 1) is a small molecule modulator of potassium ion channels showing great therapeutic potential for treating a variety of diseases characterized by dysfunction of potassium ion channels and dysfunction from other causes which influence these potassium channels. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoRimtuzalcap (CAD-1883) reduces the firing rate of Purkinje cells by approximately 40%, consistent with the anticipated therapeutic mechanism of positive allosteric modulation of SK channels. Sequential bath application of 1 or 3 µM CAD-1883 results in a partial reversal of the increased coefficient of variation of the interspike interval which is seen in cerebellar slices from 11-month-old spinocerebellar ataxia-2 58Q mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:Solid.

Specifications and Purity: ≥99%

Molecular Formula: C18H24F2N6O

Molecular Weight: 378.42

PubChem CID: 132207249

Isomeric SMILES: CC1=NN(C=C1)C2=NC(=CC(=N2)N3CCOCC3)NC4CCC(CC4)(F)F